Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Doripenem Stories

2013-10-08 12:27:18

However, Hospital Pharmacy Directors Are Less Receptive to Formulary Inclusion Of Such Premium-Priced Antibiotics, According to a New Report from Decision Resources BURLINGTON, Mass., Oct. 8, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a majority of surveyed infectious disease (ID) specialists are willing to prescribe novel antibiotics, developed under the Infectious Diseases...

2008-10-27 12:00:10

WASHINGTON, Oct. 27 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), today announced new study results that demonstrate doripenem (DORIBAX(TM), doripenem for injection), a carbapenem antibiotic, was found to be more potent in vitro against certain strains of Enterobacteriaceae, including Extended-spectrum Beta-lactamases (ESBLs) than other commonly used carbapenems. Enterobacteriaceae is a large group of bacteria that can cause...

2008-07-16 21:00:11

RARITAN, N.J., July 16 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that the U.S. Food and Drug Administration's (FDA) Anti-Infective Drugs Advisory Committee voted in favor of the efficacy and safety data for DORIBAX(TM) (doripenem for injection) for the treatment of hospital-acquired pneumonia, or nosocomial pneumonia (NP), and ventilator-associated pneumonia (VAP). The committee voted that 500 mg of DORIBAX at both the one-hour...